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Oxytocin attenuates affective evaluations of conditioned faces
and amygdala activity
Abstract
Social relations between humans critically depend on our affective experiences of others. Oxytocin
enhances prosocial behavior, but its effect on humans' affective experience of others is not known. We
tested whether oxytocin influences affective ratings, and underlying brain activity, of faces that have
been aversively conditioned. Using a standard conditioning procedure, we induced differential negative
affective ratings in faces exposed to an aversive conditioning compared with nonconditioning
manipulation. This differential negative evaluative effect was abolished by treatment with oxytocin, an
effect associated with an attenuation of activity in anterior medial temporal and anterior cingulate
cortices. In amygdala and fusiform gyrus, this modulation was stronger for faces with direct gaze,
relative to averted gaze, consistent with a relative specificity for socially relevant cues. The data suggest
that oxytocin modulates the expression of evaluative conditioning for socially relevant faces via
influences on amygdala and fusiform gyrus, an effect that may explain its prosocial effects.
Behavioral/Systems/Cognitive
Oxytocin Attenuates Affective Evaluations of Conditioned
Faces and Amygdala Activity
Predrag Petrovic, Raffael Kalisch, Tania Singer, and Raymond J. Dolan
Wellcome Trust Functional Imaging Laboratory, University College London, LondonWC1N 3BG, United Kingdom
Social relations between humans critically depend on our affective experiences of others. Oxytocin enhances prosocial behavior, but its
effect on humans’ affective experience of others is not known. We tested whether oxytocin influences affective ratings, and underlying
brain activity, of faces that have been aversively conditioned. Using a standard conditioning procedure, we induced differential negative
affective ratings in faces exposed to an aversive conditioning compared with nonconditioning manipulation. This differential negative
evaluative effectwas abolishedby treatmentwithoxytocin, an effect associatedwithanattenuationof activity in anteriormedial temporal
and anterior cingulate cortices. In amygdala and fusiform gyrus, this modulation was stronger for faces with direct gaze, relative to
averted gaze, consistent with a relative specificity for socially relevant cues. The data suggest that oxytocin modulates the expression of
evaluative conditioning for socially relevant faces via influences on amygdala and fusiform gyrus, an effect thatmay explain its prosocial
effects.
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Introduction
Social animals need to strike a balance between approach and
avoidance behavior toward others. Although avoidance may di-
minish risk of harm, approach is necessary for social activities,
including mating, protection of offspring, hunting, and group
formation. Oxytocin, a nanopeptide produced within hypotha-
lamic paraventricular nuclei, modulates these processes in ani-
mals (Insel et al., 2001; Young, 2002; Debiec, 2005; Lim and
Young, 2006) and facilitates prosocial behavior by both increas-
ing approach but also suppressing avoidance (Bartz and Hol-
lander, 2006; Hammock and Young, 2006; Carter, 2007; Hein-
richs andGaab, 2007). In humans, the state of our social relations
is often reflected in how we emotionally experience others
(Singer et al., 2006). Thus, an oxytocin effect in humans should
be evident in altered behavior (Kosfeld et al., 2005) and also in
how we affectively experience others. Here, we specifically tested
whether affective ratings of faces are modulated by oxytocin
treatment while indexing the associated neuronal correlates of
this effect.
Both threat (Phelps, 2006) and social (Haxby et al., 2002;
Adolphs and Spezio, 2006) signals activate amygdala, which in
turn modulates cortical areas involved in emotional and social
processing. One expression of this is augmentation of activity
in fusiform face area (FFA) to fearful facial expressions (Vuil-
leumier and Pourtois, 2007), in addition to influences on sub-
cortical and brainstem structures involved in behavioral fear
responses (Davis and Whalen, 2001). The amygdala contains
dense concentrations of oxytocin receptors (Insel and Sha-
piro, 1992; Veinante and Freund-Mercier, 1997) which regu-
late its activity (Huber et al., 2005). Monogamous species,
compared with polygamous species, differ in concentrations
of oxytocin receptors in several brain regions, including the
amygdala (Insel and Shapiro, 1992). An effect on amygdala
may provide a potential mechanism whereby oxytocin
influences prosocial behavior, specifically by suppressing so-
cial avoidance responses (Bartz and Hollander, 2006; Ham-
mock and Young, 2006; Carter, 2007; Heinrichs and Gaab,
2007).
In humans, it has been shown previously that oxytocin
attenuates neural responses to aversive pictures, including
emotional face expressions (Kirsch et al., 2005; Domes et al.,
2007). The behavioral relevance of this attenuation and its
implications for social cues remain unaddressed. In this study,
we assessed both the neural effects of oxytocin and its impact
on affective responses to faces associated with fear as a func-
tion of their social relevance. Our experiment involved pre-
sentation of face stimuli that had previously been fear condi-
tioned (CS) or not (CS) by pairing with shocks. We then
assessed whether oxytocin had any effect on the conditioning-
induced change in affective ratings of faces, specifically evalu-
ative conditioning effects, as our primary outcome measure.
We used stimuli that were matched closely in visual input but
differed in social relevance, with direct gaze conveying a more
salient social signal (Haxby et al., 2002). Our key hypothesis
was that oxytocin, but not placebo, treatment would attenuate
negative affective ratings of CS relative to CS faces, an
effect associated with modulation of amygdala and FFA
responses.
Received June 7, 2007; revised Dec. 13, 2007; accepted Jan. 23, 2008.
Thisworkwas supported by aWellcomeTrust ProgrammeGrant (R.J.D.). P.P.was also supported byHja¨rnfonden
and the Swedish Research Council.
Correspondence should be addressed to Predrag Petrovic, Wellcome Trust Functional Imaging Laboratory, Uni-
versity College London, 12 Queen Square, LondonWC1N 3BG, UK. E-mail: predrag.petrovic@ki.se.
DOI:10.1523/JNEUROSCI.4572-07.2008
Copyright © 2008 Society for Neuroscience 0270-6474/08/286607-09$15.00/0
The Journal of Neuroscience, June 25, 2008 • 28(26):6607–6615 • 6607
Materials andMethods
Subjects. Thirty right-handed healthy male subjects were included in the
study, which was approved by the local ethical committee (Department
of Neurology and Neurosurgery, University College London, London,
UK). The subjects had no history of mental or psychiatric disorder. Be-
fore the study, subjects provided written informed consent. Three sub-
jects were excluded from the analysis, two because they showed a high
degree of drowsiness and had closed eyes in the scanner and one because
of movement artifacts in the imaging data.
Experimental design. Subjects were first fear conditioned while brain
activity was measured using functional magnetic resonance imaging
(fMRI) (data reported elsewhere). The conditioned stimuli consisted of
four faces of different identities, two with direct gaze and two with
averted gaze (taken from George et al., 2001) (Fig. 1). Two of the faces
(CS) [one with direct gaze (CSdg) and one with averted gaze
(CSag)] were paired with an electric shock [unconditioned stimulus
(UCS)] with a 50% contingency. The other two faces (CS) [one with
direct gaze (CSdg) and one with averted gaze (CSag)] were never
paired with shock.
After fear conditioning, subjects were removed from the scanner and
instructed how to inhale a nasal spray that contained either placebo or
oxytocin (oxytocin group: n  15 subjects, mean age of 25.5 years, age
range of 19–40 years; placebo group: n 12 subjects, mean age of 24.2
years, age range of 19–39 years). Subjects were randomly assigned to each
group in a double-blind design such that none of the investigators knew
which treatment was assigned to each subject. The treatments were
coded, and the codes were opened only on completion of the entire
experiment. It has been shown previously that nanopeptides pass the
blood–brain barrier reliably after intranasal application (Born et al.,
2002). Several studies using this method have reported oxytocin-
dependent effects on behavior or brain function (Pitman et al., 1993;
Heinrichs et al., 2003, 2004; Kirsch et al., 2005; Kosfeld et al., 2005;
Domes et al., 2007a). Subjects administered the spray four times with a
delay of 45 s between administrations, each administration consisting of
one inhalation of the spray into each nostril. Every inhalation contains
4 IU such that subjects in the oxytocin group received 32 IUof oxytocin
in total.
Forty-five minutes after drug treatment, subjects were brought back
into the scanner, shock electrodes were applied, and they were tested
again. Neuronal activation to face presentations was measured using
fMRI, providing an indirect index of the strength of the aversive associ-
ations to the different CS. During this testing phase, subjects were shown
the same four faces as during conditioning but without aversive rein-
forcement through a UCS. Each face appeared 15 times for 990 ms each,
with a jittered intrastimulus time between 9000 and 12,600 ms. Order of
faces was pseudorandomized (with the restriction that the same condi-
tion could not appear three times in a row). The faces were randomly
presented either in the center or 5 mm to the right or to the left of the
center. The subject had to indicate where the face was shown as fast and
accurately as possible using three different keys on a right-hand button
box. This cognitive task was intended to ensure subjects would be atten-
tive to the stimuli and to provide a measure of conditioning-induced
changes in reaction time (RT). Skin conductance was measured contin-
uously from two electrodes on the index and middle fingers of the left
hand, using an AT64 SCR apparatus (Autogenic Systems). Both RT
changes and skin conductance responses (SCRs) to CS presentations
have been used previously as measures of fear conditioning and its ex-
pression (Gottfried and Dolan, 2004; Phelps et al., 2004; Kalisch et al.,
2006; Milad et al., 2007). Total duration of testing was 12 min.
Our primary outcomewas affective ratings in response to presentation
of faces that were exposed to a fear conditioning and nonconditioning
manipulation (Fig. 1). Before conditioning (pretreatment 1), subjects
were instructed to indicate how sympathetic each face was on a 0–100
visual-analog scale in which 0meant that that they did not perceive them
as sympathetic at all and 100meant that they perceived them as the most
sympathetic person they could imagine. The subjects again completed
the same rating after conditioning but before treatment (pretreatment 2)
and twice after treatment, once directly before the testing session (post-
treatment 1) and once directly after the testing session (posttreatment 2)
(Fig. 1). We defined an index of evaluative conditioning as a change in
Figure 1. A, Stimuli. Four different face identities were used randomized over subjects across the four conditions defined by social relevance (direct vs averted gaze) and fear conditioning (CS
vs CS). B, Design. In a conditioning session, the CS faces were paired with shock with a 50% contingency. After conditioning, subjects were treated with either oxytocin or placebo. Treatment
effects on affective associations to the faces were assessed in a testing session including likeability ratings and fMRI measurement of brain activity.
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likeability of CS minus the change in likeability of CS (because we
expected the conditioning procedure to entail a decrease in likeability of
CS vs CS faces). The pretreatment change in affective ratings was thus
defined as (ratings of CS after the conditioning phase vs ratings of CS
before the conditioning phase) versus (ratings of CS after the condi-
tioning phase vs ratings of CS before the conditioning). The evaluative
conditioning index for “posttreatment 1” rating was defined as (ratings
of CS after the treatment but before testing phase vs ratings of CS
before the conditioning phase) versus (ratings of CS after the treatment
but before testing phase vs ratings of CS before conditioning phase).
Similarly, the evaluative conditioning index for “posttreatment 2” rating
was defined as (ratings of CS after treatment and the testing phase vs
ratings of CS before the conditioning phase) versus (ratings of CS
after treatment and the testing phase vs ratings of CS before the condi-
tioning phase).
Subjects rated their subjective mood on a visual-analog scale featuring
17 pairs of words (supplemental Table 1, available at www.jneurosci.org
as supplemental material) once before conditioning (pretreatment 1)
and once after treatment directly before testing (posttreatment 1). They
also rated adverse effects on a seven-item physical symptoms rating scale
(supplemental Table 2, available at www.jneurosci.org as supplemental
material) once before conditioning (pretreatment 1), once after treat-
ment directly before testing (posttreatment 1), and once after testing
(posttreatment 2). A fear-related effect on SCR was defined as the SCR
response forCS (CSdg andCSag) versusCS (CSdg andCSag).
SCRs were Z-normalized to reduce interindividual variability (Kalisch et
al., 2006). The significance of SCR and RT effects was tested using para-
metric statistics, whereas the significance of subjective effects was as-
sessed nonparametrically. Because we performed a nonparametric anal-
ysis on the affective ratings, we primarily focused on treatment
differences in general effects of conditioning and did not include gaze in
themodel. However, in SCR and reaction time analysis, we included also
gaze in our ANOVA.
fMRI scanning and data analysis.The imaging data (T2*-weighted echo
planar images) measuring blood oxygen level-dependent contrast were
acquired using a 1.5 tesla Siemens Sonata system. We used a sequence
with axial slices tilted by 30° and a flip angle of 90° that reduces signal
dropout attributable to susceptibility-induced field inhomogeneities in
amygdala and orbitofrontal cortex (Obfc) (Deichmann et al., 2002). Our
field of view covered the whole brain in 44 planes. The repetition time
was set to 3.96 s (90msper slice) and echo time to 50ms in a single session
of 12 min, resulting in 179 volumes.
Images were processed using SPM5 (www.fil.ion.ucl.ac.uk/spm)
(Ashburner et al., 2004). Scans were realigned,
normalized, and spatially smoothed by an 8mm
full-width half-maximum Gaussian kernel. A
high-pass filter (with a cutoff at 128 s) was ap-
plied to the time series. The data were then an-
alyzed in an event-related manner.
We modeled conditions for each subject
within a fixed-effects general linear model. The
resulting beta estimate maps were then taken to
a second-level group analysis, and the signifi-
cance of contrasts of interest was assessedwithin
a random-effects framework to allow statistical
inference across the population. On the second
level, we used unpaired two-sample t tests to
assess the difference in activations between the
oxytocin and the placebo groups.
Our focus of interest in this study was a net-
work of predefined regions involved in process-
ing of fear-related stimuli and faces that in-
cluded amygdala, FFA, insula, anterior
cingulate cortex (ACC), and Obfc (Phelps,
2006; Vuilleumier and Pourtois, 2007). We re-
port all activations in these regions as significant
when p  0.001 uncorrected, except for the
amygdala, in which we applied a region of inter-
est [(24, 3, 24); radius, 8 mm] based on a
previous study on oxytocin modulation of fear
processing (Kirsch et al., 2005) and performed a small volume correction
with a threshold of p 0.05.
Results
Oxytocin effects on affective evaluations
In linewith previous studies inwhich oxytocinwas administrated
externally (Pitman et al., 1993;Heinrichs et al., 2003, 2004; Kirsch
et al., 2005; Kosfeld et al., 2005; Domes et al., 2007a), we did not
observe any significant effect onmood ratings (supplemental Ta-
ble 1, available at www.jneurosci.org as supplemental material).
Oxytocin induced no adverse effects over the course of the exper-
iment (supplemental Table 2, available at www.jneurosci.org as
supplemental material).
Changes in likeability ratings for faces, induced by fear condi-
tioning, de facto reflecting evaluative conditioning (seeMaterials
and Methods) constituted our primary outcome measure. After
conditioning (pretreatment 2), faces paired with shock (CS)
were perceived as less sympathetic, whereas faces never paired
with shock (CS) were perceived as more sympathetic relative to
ratings acquired before conditioning (pretreatment 1) (see sup-
plemental data, available at www.jneurosci.org as supplemental
material). Within the oxytocin assigned group, four subjects
showed no effect of conditioning on affective ratings. To ensure
homogeneity of treatment groups, all additional analysis was per-
formed only on “responders” to our conditioning manipulation
(oxytocin group: n 11 subjects, mean age of 25 years, age range
of 19–40 years; placebo group: n 12 subjects, mean age of 25.5
years, age range of 19–39 years). However, for completeness, we
also performed an analysis that included all subjects, which
showed that removing these four subjects had no impact on over-
all results (supplemental data, available at www.jneurosci.org as
supplemental material).
Figure 2A shows the evolution of affective ratings over time in
the two treatment groups. The evaluative conditioning index (see
Materials and Methods) was significantly greater in the placebo
compared with the oxytocin group at posttreatment 1 (oxytocin
group average SD, 5.273 18.03; placebo group average SD,
15.58  18.08; Wilcoxon’s signed-rank test, Z  2.156, p 
0.05) and posttreatment 2 time points (oxytocin group average
Figure 2. A, Absolute likeability ratings in the oxytocin (left) and placebo (right) groups before and after conditioning (pre-
treatment 1 and 2) and before and after testing (posttreatment 1 and 2). B, Reduced likeability-based normalized evaluative
conditioning index after oxytocin treatment. C, Reaction times to CS and CS stimuli during testing in the two treatment
groups. Slowing of CS reaction times characteristic of evaluative conditioning recall was abolished by oxytocin. Error bars
indicate SE. *, Significant; (*), threshold significance; n.s., nonsignificant. For p values, see Results.
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SD,2.454 7.610; placebo group average SD, 14.95 20.30;
Wilcoxon’s signed-rank test, Z  2.124, p  0.05). These re-
sults indicate that an induced evaluative change after condition-
ing was attenuated by oxytocin.
A closer analysis of these data indicated variability in how
subjects rated the faces. Consequently, we performed an analysis
in which the pretreatment conditioning-induced change in affec-
tive ratings was normalized to 1 (Fig. 2B). Thus, change in ratings
after administration of oxytocin was now expressed as the degree
of evaluative conditioning effect remaining after treatment (for
design, see Fig. 1B). This normalization, which controls for skew-
ing of data, showed a significant difference between oxytocin and
placebo groups in that posttreatment affective ratings, whereby
the conditioning effects were significantly stronger in the placebo
group before the testing (fMRI extinction) session (oxytocin
group average SD,0.157 1.002; placebo group average
SD, 0.522 0.747;Wilcoxon’s signed-rank test,Z1.723, p
0.05), whereas the effects showed a trend level difference after the
testing session (oxytocin group average  SD, 0.187  1.338;
placebo group average  SD, 0.6148  0.739; Wilcoxon’s
signed-rank test, Z  1.477, p  0.075). The results indicate
that an index of evaluative conditioning of faces was attenuated
by oxytocin. Post hoc, we tested whether oxytocin had an overall
effect on ratings, regardless of the whether the stimulus was CS
or CS and found no such evidence [before testing condition
(posttreatment 1):Wilcoxon’s signed-rank test,Z0.348, p
0.733; after testing condition (posttreatment 2): Wilcoxon’s
signed-rank test, Z0.319, p 0.766].
Oxytocin effects on RTs and SCRs
Gaze did not have any effect on RT in an initial mixed three-way
ANOVA (the two other factors were conditioning and treat-
ment). For simplicity, we collapsed gaze conditions and per-
formed a mixed ANOVA with within-subject factor fear condi-
tioning (CS and CS) and between-subject factor treatment
(oxytocin and placebo) (Fig. 2C). This analysis showed a signifi-
cant conditioning  treatment interaction (F(1,22)  5.234; p 
0.05). The interaction was driven by a differential slowing of RTs
to the CS (average  SD RT, 597.4  86.4 ms) versus CS
(average  SD, r  577.6  75.7 ms) in the placebo group that
was not present in the oxytocin group (average SDRT forCS:
636.6  96.8 ms; average  SD RT for CS: 647.9  118.5 ms)
(Fig. 2C). Slowing of CS relative to CS RTs during a testing
phase after conditioning has been reported previously (Kalisch et
al., 2006) and is likely to reflect interference of emotion on a
simultaneous cognitive task (Mathews et al., 1997). The results
further confirm an attenuation of evaluative conditioning by
oxytocin. Therewas nomain effect of treatment for RT (F 1.96;
p 0.176). SCRs appeared to habituate quickly during the testing
session for most subjects, and no differential (CS vs CS) ef-
fects of conditioning were observed, again in agreement with our
previous study (Kalisch et al., 2006) in which fear memory recall
at test was accompanied by differential RT, but not SCR, effects.
Effects of oxytocin on evaluative fear processing in fMRI
The main effects of evaluative fear conditioning (CS  CS)
during the testing session in the two treatment groups are shown
in Table 1. In the placebo group, we observed increased activity in
the extended/dorsal amygdala and in other regions previously
shown to be involved in fear conditioning and extinction such as
insula, Obfc, and ACC (Gottfried and Dolan, 2004; Phelps et al.,
2004; Kalisch et al., 2006; Milad et al., 2007). Activation of these
regions [apart from an activation of rostral ACC (rACC) and
Obfc] was not observed in the oxytocin group. Crucially, a sig-
nificant evaluative conditioning  treatment interaction [(CS
CS)placebo (CS
CS)oxytocin] was evident in an anterior
medial temporal cortex (with a maximum in piriform cortex just
anterior to amygdala but extending into amygdala proper) and in
the ACC, with the placebo group showing higher activation (Ta-
ble 1; Fig. 3A).
Simple main effects of evaluative fear conditioning for faces
displaying direct gaze (CSdgCSdg) are shown inTable 2. In
the placebo group, we observed increased activity in caudal ACC,
right FFA (Fig. 4), and at trend level significance in bilateral
amygdala. In the oxytocin group, we observed activation in cau-
dal ACC and ventrolateral prefrontal cortex (vlPFC). A signifi-
cant fear conditioning  treatment interaction [(CSdg 
CSdg)placebo (CSdg
  CSdg)oxytocin) was observed in the
right amygdala, caudal, rostral, and subgenual ACC, and right
FFA, with the placebo group again showing higher activation
(Table 2; Figs. 3B, 4C). Simple main effects of fear conditioning
for the faces displaying averted gaze (CSagCSag) are shown
inTable 3. The insulawas activated in both groups.No significant
evaluative fear conditioning treatment interaction [(CSag
CSag)placebo  (CSag
  CSag)oxytocin] was observed in in-
sula, FFA, amygdala, or caudal ACC.
It can be conjectured that activity elicited by socially relevant
cues, in our experiment direct as opposed to averted-gaze faces,
should be more susceptible to oxytocin. Therefore, we examined
for a three-way interaction between fear conditioning (CS and
Table 1. Main effects in fMRI of fear conditioning (CS> CS) in placebo and oxytocin groups and their interaction
Placebo group Oxytocin group Difference placebo versus oxytocin group
Coordinates t value p value Coordinates t value p value Coordinates t value p value
Dorsal/Ext Amy 18, 2,8 3.68 0.001 20, 0,8 2.75 NS
Ant MTL 16, 8,24 3.70 0.05*
R Insula 48, 4, 6 3.48 0.001
L Insula 36, 16,10 3.72 0.001
vmPFC 14, 46,10 3.50 0.001 16, 46,10 3.66 0.001
vmPFC 20, 56,6 3.77 0.001
R lObfc 44, 54,12 4.51 0.001 20, 56,6 5.00 0.001
L lObfc 40, 52,6 3.80 0.001
L ACC 14, 14, 40 3.63 0.001
R ACC 10, 10, 42 3.95 0.001 10, 10, 44 4.75 0.001
R rACC 12, 34, 12 3.58 0.001 6, 46, 16 3.57 0.001
vlPFC 48, 46, 2 3.64 0.001 50, 32, 8 4.13 0.001
Dorsal Amy, Dorsal amygdala; Ext Amy, extended amygdala; Ant MTL, anterior medial temporal lobe; vmPFC, ventromedial prefrontal cortex; vlPFC, ventrolateral prefrontal cortex; rACC, rostral anterior cingulate cortex; R, right; L, left; NS,
nonsignificant. *Small volume corrected.
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CS), treatment (oxytocin and placebo), and social relevance
(direct gaze and averted gaze). There was a significant interaction
in right amygdala, driven by enhanced responses to fear-
conditioned faces with direct gaze in the placebo group (Table 4;
Fig. 3C,D). The right FFA, rACC, and vlPFC showed a similar
interaction (Table 4).
Discussion
Animal studies have shown that oxytocin is involved in regulating
social interactions, mediating increased approach behavior to-
ward conspecifics (Lim and Young, 2006). Oxytocin is also im-
plicated in inhibition of fear-related processes (Debiec, 2005). It
has been hypothesized that these two effects are functionally re-
lated and that oxytocin mediates its prosocial behavior partly
through suppression of avoidance-related processes (Lim and
Young, 2006). One possibility is that oxytocin influences fear-
related social stimuli more than fear-related nonsocial stimuli.
Although social cues are mostly conveyed through the olfactory
system in rodents, in which the oxytocin system has been most
extensively studied, in humans social cues depend on the visual
system, as exemplified by face processing (Haxby et al., 2002;
Adolphs et al., 2005; Lim and Young, 2006). Moreover, because
social-affective responses are modified with respect to our expe-
rience of others (Singer et al., 2006), we conjectured that oxytocin
might modulate this dimension. This sug-
gests that oxytocin effects on fear-related
social stimuli should be evident in attenu-
ated affective ratings and attenuated brain
responses within regions processing so-
cially relevant stimuli (i.e., faces).
The best characterization of postcondi-
tioning change in affective ratings and their
modulation by oxytocin is that mediated
by evaluative conditioning (De Houwer et
al., 2001). Our demonstration of an atten-
uation in affective ratings for fear-related
faces by oxytocin is in line with the hypoth-
esis that oxytocin-mediated prosocial pro-
cesses involve a suppression of aversive as-
sociations to specific stimuli (Lim and
Young, 2006). It has been shown previ-
ously that oxytocin has prosocial effects in
humans, as in oxytocin treatment influenc-
ing trust behavior in economic games (Ko-
sfeld et al., 2005), modulating inferences
regarding others’ mental states (Domes et
al., 2007a), and reducing stress in social in-
teractions (Pitman et al., 1993;Heinrichs et
al., 2003; Domes et al., 2007a). Impor-
tantly, in our study, oxytocin had no effect
onmood, in linewith previous studies (Pit-
man et al., 1993; Heinrichs et al., 2003,
2004; Kirsch et al., 2005; Kosfeld et al.,
2005; Domes et al., 2007a), but did impact
on acquired negative affective ratings re-
lated to social stimuli.
We observed a significant effect of oxy-
tocin on the amygdala, a region implicated
in fear processing, including fear learning
(Phelps, 2006). The amygdala also plays a
key role in processing social cues such as
direction of eye gaze, manifest in an en-
hanced amygdala response to direct com-
pared with averted gaze (Kawashima et al.,
1999; George et al., 2001;Haxby et al., 2002; Adolphs et al., 2005).
These two dimensions, fear and social cue processing, interact in
the amygdala as when a face signals threat (Vuilleumier and
Pourtois, 2007) and in judgment of untrustworthiness (Winston
et al., 2002). The fact that the amygdala expresses high concen-
trations of oxytocin receptors (Insel and Shapiro, 1992; Veinante
and Freund-Mercier, 1997; Huber et al., 2005), which act by in-
hibiting activity in the basolateral amygdala through the influ-
ence of GABA (Huber et al., 2005), provides a likely mechanisms
bywhich oxytocinmight induce specific effects on socially related
fear (Debiec, 2005).
Two previous human studies have reported reduced fear-
related activation of amygdala after oxytocin (Kirsch et al., 2005;
Domes et al., 2007). However, unlike the present report, these
studies lacked a relevant behavioral measure. Moreover, because
social and nonsocial stimuli were not matched, it is not possible
to dissociate whether oxytocin has a stronger effect on socially
relevant stimuli associated with the same degree of fear. It is this
specificity of oxytocin for stimuli with a higher social value that is
the novel finding reported here. Specifically, we show attenuated
activation of the anterior medial temporal region for fear-related
stimuli in the oxytocin group, an effect expressed to a greater
degree for faces displaying direct gaze compared with averted
Figure3. Oxytocinmodulates processing of socially relevant fear stimuli in the amygdala.A, Neural responses to CS relative
toCS face stimuli are stronger in theplacebo than in theoxytocingroup inanteriormedial temporal lobe (aMTL) andACC [(CS
 CS)placebo (CS
 CS)oxytocin: (x, y, z) (16, 8,24); t 3.70 and (x, y, z) (10, 10, 44); t 4.75, respectively].
B, Similar treatment effects were observed in the amygdala (Amy) when restricting the analysis to faces displaying direct gaze
only [(CSdg CSdg)placebo (CSdg
 CSdg)oxytocin: (x, y, z) (18, 2,20); t 3.45]. C, In a three-way ANOVA, a
comparison of direct- versus averted-gaze faces as a function of fear processing showed larger activation for direct gaze [(CSdg
 CSdg) (CSag  CSag) in the placebo group than the oxytocin group: (x, y, z) (20, 0,20); t 3.55]. All
activations are superimposed on amean structural image and thresholded at p 0.005.D, Parameter estimates characterizing
the three-way interaction between fear conditioning, gaze, and treatment. Error bars indicate SE.
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gaze, consistent with a specific modulation of socially relevant
threat stimuli (Kawashima et al., 1999; George et al., 2001; Haxby
et al., 2002; Adolphs et al., 2005). It is important to stress that
both averted- anddirect-gaze faces are social stimuli.However, in
direct gaze, attention is toward the individual, and in averted
gaze, the attention is directed toward an extrapersonal spatial
location. Thus, although the difference is subtle and the faces are
highly matched, it has been suggested that direct gaze is more
socially relevant (Haxby et al., 2002).
The amygdala showed significantly stronger activation to
fear-related faces displaying direct gaze than averted gaze un-
der placebo, although the behavioral results did not suggest
any differences in evaluative conditioning strength. The fact
that there is lack of congruency between amygdala and behav-
ioral data means we cannot reach a strong conclusion that
amygdala activity drives a difference in affective ratings. There
are several possible explanations for the observed differences.
First, behavioral effects, like affective ratings or reaction times,
are noisy measurements and may not be as sensitive as a direct
measure of brain activity (for example, see Meyer-Lindenberg
et al., 2005). Thus, it is possible that there is a relationship
between amygdala specificity for direct gaze and affective rat-
ings but that this study lacks power to show such a relation-
ship. Another possibility is that the specific modulation of
amygdala for direct gaze represents another process unrelated
to the change in affective ratings. Other regions such as the
Table 2. Simplemain effects of fear conditioning for direct gaze faces (CSdg> CSdg) in the placebo and oxytocin groups
Placebo group Oxytocin group Difference placebo versus oxytocin group
Coordinates t value p value Coordinates t value p value Coordinates t value p value
Amy 20, 0,18 2.63 NS 18, 2,20 3.45 0.05*
Amy 14,8,22 2.65 NS
R Insula 40, 32,8 3.30 NS
L Insula
cACC 16, 10, 52 3.95 0.001 16, 2, 36 4.48 0.001 14, 8, 46 4.01 0.001
cACC 16, 10, 46 3.50 0.001 16, 10, 44 3.58 0.001
subgACC 14, 44,8 4.20 0.001
vlPFC 48, 48, 4 3.89 0.001 48, 48, 4 4.73 0.001
vlPFC 50, 32, 10 4.72 0.001 50, 32, 6 5.01 0.001
mObfc 18, 54,6 4.60 0.001
R FFA 36,54,12 4.47 0.001 38,54,12 3.71 0.001
Amy,Amygdala; cACC, caudal anterior cingulate cortex; subgACC, subgenual ACC; vlPFC, ventrolateral prefrontal cortex;mObfc,medial orbitofrontal cortex; FFA, fusiform face area; R, right; L, left; NS, nonsignificant. *Small volume corrected.
Figure4. Oxytocinmodulates processing of socially relevant fear-conditioned stimuli in the fusiformgyrus.A–C, Processing of conditioned faces displayingdirect gaze (CSdg CSdg) in the
FFA in the placebo group [(x, y, z) (36,54,12); t 4.47] (A) and in the oxytocin group (same coordinate, no activation in FFA) (B) and the difference between the treatment groups [(x, y,
z) (38,54,12); t 3.71] (C). D, Parameter estimates for the interaction in C. Error bars indicate SE. Activations are shown thresholded at p 0.005.
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ACC that is involved in processing affective and conditioned
stimuli (Phelps, 2006) may be important for the observed ef-
fects on evaluative conditioning. This region showed a general
oxytocin-dependent attenuation for CS faces in the present
study and contains high concentrations of oxytocin receptors
in monogamous species (Insel and Shapiro, 1992). Thus, the
effect of oxytocin may be more complex than just involving an
amygdala modulation. At the very least, our data suggest that
oxytocin is more effective in modulating the amygdala re-
sponse for socially relevant stimuli because these stimuli are
more prone to activate amygdala than less socially relevant
stimuli when associated with fear. The alternative hypothesis,
namely that both social and nonsocial fear-related stimuli ac-
tivate amygdala equally but only social-specific stimuli are
modulated by oxytocin, seems less likely given the present
results.
We also observed fear-related activation in right FFA for
faces displaying direct gaze in the placebo group, an effect
attenuated in the oxytocin group. It has been suggested previ-
ously that the FFA processes face identity (Kawashima et al.,
1999; George et al., 2001; Haxby et al., 2002) especially when
the face signals threat (Morris et al., 1998; Vuilleumier et al.,
2001) and that this interaction between face and fear process-
ing is dependent on amygdala influences (Vuilleumier et al.,
2004). Thus, the attenuated FFA activity for fear-related faces
in the oxytocin group may be a consequence of attenuated
amygdala activity. This finding underlines the fact that oxyto-
cin does not just suppress general fear-related responses but
also processing of specific identities associated with threat, in
line with evidence that prosocial processes involve suppres-
sion of negative associations to specific individuals (Lim and
Young, 2006). At first glance, this might seem to conflict with
findings that oxytocin receptor knock-out mice have lower
social recognition of conspecifics (Ferguson et al., 2002; Biel-
sky and Young, 2004). However, we note that tasks in these
studies addressed approach and not avoidance behavior, rais-
ing the possibility that oxytocin induces prosocial behavior
not through augmenting social memory related to approach
but suppressing social memory related to avoidance. Interest-
ingly, for averted faces, we observed no significant fear-related
activation in FFA in the placebo group, nor any difference
between the treatment groups. Thus, as for the amygdala, FFA
responds more reliably to social relevant cues associated with
threat.
Deficits in processing social cues are evident in clinical
populations such asWilliams syndrome and autism. Both syn-
dromes involve abnormal processing of faces: although amyg-
dala activation is heightened in autism for faces with direct
gaze (Dalton et al., 2005), it is suppressed in Williams syn-
drome for fearful faces (Meyer-Lindenberg et al., 2005). Pa-
tients with Williams syndrome show high sociability and em-
pathy (Meyer-Lindenberg et al., 2006), whereas autistic people
show impaired social functioning (Hill and Frith, 2003).
Moreover, the amount of time autistic subjects fixate on eyes
direct gazing at the observer correlates with amygdala and
fusiform activity (Dalton et al., 2005). It has been suggested
that an underlying cause for deficits in social interaction in
autistics is a malfunctioning oxytocin system (Bartz and Hol-
lander, 2006; Hammock and Young, 2006; Carter, 2007; Hei-
nrichs and Gaab, 2007), evidenced in lower oxytocin levels
than in normal controls (Modahl et al., 1998; Green et al.,
2001) and an association with specific variants of the oxytocin
receptor gene (Wu et al., 2005; Ylisaukko-oja et al., 2006). The
present study shows that processing of socially relevant cues
related to fear are attenuated by oxytocin, raising the issue as
to whether oxytocin might improve social interactions in au-
Table 3. Simplemain effects of fear conditioning for averted gaze faces (CSag> CSag) in the placebo and oxytocin groups
Placebo group Oxytocin group Difference placebo versus oxytocin group
Coordinates t value p value Coordinates t value p value Coordinates t value p value
Dorsal/Ext Amy 22,4,10 3.26 NS 20,2,10 2.17 NS
R Insula 40, 22, 2 4.18 0.001 34, 20, 2 3.29 NS
L Insula 32, 20, 6 4.89 0.001
rACC/vmPFC 12, 48, 18 4.20 0.001 8, 50, 6 3.49 0.001
dmPFC
mObfc 20, 60,4 4.74 0.001 18, 44,16 3.42 0.001
lObfc 30, 42,12 3.39 0.001
lObfc 28, 56, 8 3.46 0.001
vlPFC 32, 60, 2 3.55 0.001 40, 36, 0 3.69 0.001
Dorsal Amy, Dorsal amygdala; Ext Amy, extended amygdala; rACC, rostral anterior cingulate cortex; vmPFC, ventromedial prefrontal cortex; dmPFC, dorsomedial prefrontal cortex; mObfc, medial orbitofrontal cortex; lObfc, lateral
orbitofrontal cortex; vlPFC, ventrolateral prefrontal cortex; R, right; L, left; NS, nonsignificant.
Table 4. Interaction between faces displaying direct and averted gaze in the placebo and oxytocin group 	(CSdg vs CSdg) vs (CSag vs CSag)

Placebo group Oxytocin group Difference placebo oxytocin group
Coordinates t value p value Coordinates t value p value Coordinates t value p value
Amy 20, 0,20 3.94 0.05* 20, 0,20 3.55 0.05*
Amy 18,8,26 2.56 NS
R Insula 30, 30,10 3.66 0.001
R FFA 42,50,14 4.58 0.001 42,50,14 3.59 0.001
cACC 14, 0, 40 3.89 0.001
12,2, 48 4.04 0.001
mObfc 16, 44,18 3.89 0.001
rACC/vmPFC 4, 62, 0 5.60 0.001 4, 62, 0 4.16 0.001
vlPFC 34, 62, 4 3.73 0.001
vlPFC 46, 50, 4 4.37 0.001
Amy,Amygdala; FFA, fusiform facearea; cACC, caudal anterior cingulate cortex;mObfc,medial orbitofrontal cortex; rACC, rostral anterior cingulate cortex; vmPFC, ventromedial prefrontal cortex; vlPFC, ventrolateral prefrontal cortex; R, right;
NS, nonsignificant. *Small volume corrected.
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tistics in line with recent data showing that oxytocin appar-
ently alleviates other symptoms in autistic disorder (Bartz and
Hollander, 2006).
In conclusion, we show that oxytocin attenuates social fear
processing, consistent with animal studies in which this effect is
suggested to underlie approach to conspecific individuals and
that, in humans, it translates behaviorally into a modulation of
evaluative fear-conditioned responses, including a suppression
of fear-induced affective ratings. Moreover, we show that the
effect of oxytocin on affective face processing is expressed not
only within the amygdala, as shown previously, but also by other
regions processing specific social cues such as the fusiform gyrus.
Finally, we observed that the fMRI effects in these regions were
different depending on gaze both during general fear processing
and attributable to oxytocin treatment, suggesting that social
cues interact with these processes. The findings suggest that oxy-
tocinmay have an effect in disorders in which social impairments
are a key feature.
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